The gut microbiome in atherosclerotic cardiovascular disease

The gut microbiota has been linked to cardiovascular diseases. However, the composition and functional capacity of the gut microbiome in relation to cardiovascular diseases have not been systematically examined. Here, we perform a metagenome-wide association study on stools from 218 individuals with atherosclerotic cardiovascular disease (ACVD) and 187 healthy controls. The ACVD gut microbiome deviates from the healthy status by increased abundance of Enterobacteriaceae and Streptococcus spp. and, functionally, in the potential for metabolism or transport of several molecules important for cardiovascular health. Although drug treatment represents a confounding factor, ACVD status, and not current drug use, is the major distinguishing feature in this cohort. We identify common themes by comparison with gut microbiome data associated with other cardiometabolic diseases (obesity and type 2 diabetes), with liver cirrhosis, and rheumatoid arthritis. Our data represent a comprehensive resource for further investigations on the role of the gut microbiome in promoting or preventing ACVD as well as other related diseases.The gut microbiota may play a role in cardiovascular diseases. Here, the authors perform a metagenome-wide association study on stools from individuals with atherosclerotic cardiovascular disease and healthy controls, identifying microbial strains and functions associated with the disease.

[1]  F. Bushman,et al.  Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis , 2013, Nature Medicine.

[2]  Susumu Goto,et al.  KEGG for integration and interpretation of large-scale molecular data sets , 2011, Nucleic Acids Res..

[3]  Timothy L. Tickle,et al.  Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment , 2012, Genome Biology.

[4]  Lynne S Cairns,et al.  A mechanical signal transmitted by the flagellum controls signalling in Bacillus subtilis , 2013, Molecular microbiology.

[5]  Mathieu Almeida,et al.  Dietary intervention impact on gut microbial gene richness , 2013, Nature.

[6]  Qiang Feng,et al.  The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment , 2015, Nature Medicine.

[7]  Matthew A. Zapala,et al.  Multivariate regression analysis of distance matrices for testing associations between gene expression patterns and related variables , 2006, Proceedings of the National Academy of Sciences.

[8]  G. Maskarinec,et al.  The Influence of Whole Grain Products and Red Meat on Intestinal Microbiota Composition in Normal Weight Adults: A Randomized Crossover Intervention Trial , 2014, PloS one.

[9]  P. Bork,et al.  Richness of human gut microbiome correlates with metabolic markers , 2013, Nature.

[10]  Zeneng Wang,et al.  Intestinal Microbial Metabolism of Phosphatidylcholine and Cardiovascular Risk , 2013 .

[11]  Fredrik H. Karlsson,et al.  Gut metagenome in European women with normal, impaired and diabetic glucose control , 2013, Nature.

[12]  C. Loria,et al.  Serum folate and cardiovascular disease mortality among US men and women. , 2000, Archives of internal medicine.

[13]  Jun Wang,et al.  Metagenome-wide association studies: fine-mining the microbiome , 2016, Nature Reviews Microbiology.

[14]  Jingyuan Fu,et al.  Proton pump inhibitors affect the gut microbiome , 2015, Gut.

[15]  Rob Knight,et al.  Human oral, gut, and plaque microbiota in patients with atherosclerosis , 2010, Proceedings of the National Academy of Sciences.

[16]  K. Rajakumar,et al.  Carnitine metabolism to trimethylamine by an unusual Rieske-type oxygenase from human microbiota , 2014, Proceedings of the National Academy of Sciences.

[17]  Herbert Tilg,et al.  Gut microbiome development along the colorectal adenoma-carcinoma sequence , 2015 .

[18]  S. Hazen,et al.  γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. , 2014, Cell metabolism.

[19]  E. Balskus,et al.  Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme , 2012, Proceedings of the National Academy of Sciences.

[20]  P. Vandamme,et al.  Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives , 2011, Gut.

[21]  Stephen R. Clark,et al.  Characterization of platelet aminophospholipid externalization reveals fatty acids as molecular determinants that regulate coagulation , 2013, Proceedings of the National Academy of Sciences.

[22]  Jens Roat Kultima,et al.  Disentangling the effects of type 2 diabetes and metformin on the human gut microbiota , 2015, Nature.

[23]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[24]  Pierre Legendre,et al.  DISTANCE‐BASED REDUNDANCY ANALYSIS: TESTING MULTISPECIES RESPONSES IN MULTIFACTORIAL ECOLOGICAL EXPERIMENTS , 1999 .

[25]  Brian H. McArdle,et al.  FITTING MULTIVARIATE MODELS TO COMMUNITY DATA: A COMMENT ON DISTANCE‐BASED REDUNDANCY ANALYSIS , 2001 .

[26]  S. Taylor-Robinson,et al.  Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. , 2014, American journal of physiology. Gastrointestinal and liver physiology.

[27]  H. Bisgaard,et al.  Metagenomic heterogeneity explains dual immune effects of endotoxins. , 2015, The Journal of allergy and clinical immunology.

[28]  Jens Roat Kultima,et al.  Identification and assembly of genomes and genetic elements in complex metagenomic samples without using reference genomes , 2014, Nature Biotechnology.

[29]  V. Tremaroli,et al.  Dynamics and Stabilization of the Human Gut Microbiome during the First Year of Life. , 2015, Cell host & microbe.

[30]  J. Clemente,et al.  Human gut microbiome viewed across age and geography , 2012, Nature.

[31]  Beiwen Zheng,et al.  Alterations of the human gut microbiome in liver cirrhosis , 2014, Nature.

[32]  Morris A. Swertz,et al.  Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity , 2016, Science.

[33]  Brian J. Bennett,et al.  Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease , 2011, Nature.

[34]  E. Segal,et al.  Personalized Nutrition by Prediction of Glycemic Responses , 2015, Cell.

[35]  Alexander Reinecke,et al.  Detection of Diverse Bacterial Signatures in Atherosclerotic Lesions of Patients With Coronary Heart Disease , 2006, Circulation.

[36]  C. Elson,et al.  Microbiota , 2010, Gut microbes.

[37]  Rachel E. Klevit,et al.  Recognition of Antimicrobial Peptides by a Bacterial Sensor Kinase , 2005, Cell.

[38]  L. Appel,et al.  Effects of the Dietary Approaches to Stop Hypertension (DASH) Diet and Sodium Intake on Serum Uric Acid , 2016, Arthritis & rheumatology.

[39]  K. Wilson,et al.  Ribosomal DNA Sequence Analysis of Mucosa-Associated Bacteria in Crohn’s Disease , 2004, Inflammatory bowel diseases.

[40]  Jian Yang,et al.  VFDB 2012 update: toward the genetic diversity and molecular evolution of bacterial virulence factors , 2011, Nucleic Acids Res..

[41]  S. Hazen,et al.  Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk , 2016, Cell.

[42]  David Torrents,et al.  Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug , 2017, Nature Medicine.

[43]  Fredrik H. Karlsson,et al.  Symptomatic atherosclerosis is associated with an altered gut metagenome , 2012, Nature Communications.

[44]  Judith Aron-Wisnewsky,et al.  The gut microbiome, diet, and links to cardiometabolic and chronic disorders , 2016, Nature Reviews Nephrology.

[45]  Anders F. Andersson,et al.  A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. , 2010, Gastroenterology.

[46]  Xun Xu,et al.  Integrated metabolomics and metagenomics analysis of plasma and urine identified microbial metabolites associated with coronary heart disease , 2016, Scientific Reports.

[47]  D. Sinderen,et al.  Gut microbiota composition correlates with diet and health in the elderly , 2012, Nature.

[48]  Huijue Jia,et al.  Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention , 2017, Nature Medicine.

[49]  Qiang Feng,et al.  A metagenome-wide association study of gut microbiota in type 2 diabetes , 2012, Nature.

[50]  August Böck,et al.  The molecular biology of formate metabolism in enterobacteria. , 2002, Journal of molecular microbiology and biotechnology.

[51]  Emily R. Davenport,et al.  Genetic Determinants of the Gut Microbiome in UK Twins. , 2016, Cell host & microbe.

[52]  K. Sauer,et al.  Bacteria Present in Carotid Arterial Plaques Are Found as Biofilm Deposits Which May Contribute to Enhanced Risk of Plaque Rupture , 2014, mBio.

[53]  Ian J. Brown,et al.  Human metabolic phenotype diversity and its association with diet and blood pressure , 2008, Nature.

[54]  Beau Dabbs,et al.  Summary and discussion of : “ Controlling the False Discovery Rate : A Practical and Powerful Approach to Multiple Testing , 2014 .

[55]  Noah Simon,et al.  A Sparse-Group Lasso , 2013 .

[56]  Duy Tin Truong,et al.  Strain-level microbial epidemiology and population genomics from shotgun metagenomics , 2016, Nature Methods.

[57]  J. Clemente,et al.  The Impact of the Gut Microbiota on Human Health: An Integrative View , 2012, Cell.

[58]  John D. Storey.  A direct approach to false discovery rates , 2002 .

[59]  Jun Wang,et al.  Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota , 2015, Nature.

[60]  Jens Roat Kultima,et al.  An integrated catalog of reference genes in the human gut microbiome , 2014, Nature Biotechnology.

[61]  J. Nielsen,et al.  Uncovering transcriptional regulation of metabolism by using metabolic network topology. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[62]  G. Spindler,et al.  An Integrative View , 1992 .

[63]  H. Neu,et al.  Inactivation of digoxin by Eubacterium lentum, an anaerobe of the human gut flora. , 1982, Transactions of the Association of American Physicians.

[64]  Tim D Spector,et al.  Proton pump inhibitors alter the composition of the gut microbiota , 2015, Gut.

[65]  P. Turnbaugh,et al.  Predicting and Manipulating Cardiac Drug Inactivation by the Human Gut Bacterium Eggerthella lenta , 2013, Science.

[66]  S. Hazen,et al.  Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis , 2015, Cell.